Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AV 101

Drug Profile

AV 101

Alternative Names: 4-Chlorokynurenine - VistaGen; 4-CL-KYN; 7-CL-KYNA; AV-101; L-4-chlorokynurenine; L-4-CL-KYN

Latest Information Update: 17 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Artemis Neuroscience
  • Developer Aerovate Therapeutics; Baylor College of Medicine; National Institute of Mental Health; VistaGen Therapeutics
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antihypertensives; Antiparkinsonians; Behavioural disorder therapies; Butyric acids; Neuroprotectants; Small molecules
  • Mechanism of Action Kynurenine modulators; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypertension
  • Phase II Major depressive disorder
  • Phase I Neurological disorders
  • No development reported Epilepsy; Huntington's disease; Neuropathic pain; Parkinson's disease; Psychiatric disorders; Suicidal ideation

Most Recent Events

  • 13 Jul 2023 VistaGen receives patent allowance for AV-101 in Canada
  • 06 Apr 2023 VistaGen Therapeutics has patent protection for AV 101 in European Union
  • 28 Feb 2023 No recent reports of development identified for preclinical development in Psychiatric-disorders in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top